Equities analysts predict that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will report earnings per share (EPS) of $0.04 for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Tabula Rasa HealthCare’s earnings. The lowest EPS estimate is ($0.03) and the highest is $0.08. Tabula Rasa HealthCare reported earnings per share of $0.21 during the same quarter last year, which indicates a negative year over year growth rate of 81%. The company is scheduled to announce its next earnings report on Thursday, February 27th.
According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year earnings of $0.69 per share for the current financial year, with EPS estimates ranging from $0.63 to $0.73. For the next fiscal year, analysts anticipate that the firm will post earnings of $0.92 per share, with EPS estimates ranging from $0.75 to $1.14. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Tabula Rasa HealthCare.
Tabula Rasa HealthCare (NASDAQ:TRHC) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Tabula Rasa HealthCare had a negative net margin of 13.46% and a positive return on equity of 0.50%. The business had revenue of $74.27 million for the quarter, compared to the consensus estimate of $75.37 million.
A number of analysts have issued reports on the company. Cantor Fitzgerald cut their target price on Tabula Rasa HealthCare from $99.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. ValuEngine lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 13th. BidaskClub cut Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Monday, January 6th. Piper Jaffray Companies dropped their price objective on Tabula Rasa HealthCare from $78.00 to $66.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Finally, Wells Fargo & Co cut their price objective on Tabula Rasa HealthCare from $55.00 to $50.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $66.79.
Shares of NASDAQ:TRHC traded up $1.31 during mid-day trading on Thursday, reaching $52.86. 4,121 shares of the company were exchanged, compared to its average volume of 329,321. Tabula Rasa HealthCare has a 1 year low of $37.41 and a 1 year high of $68.99. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.22 and a quick ratio of 2.13. The firm’s 50-day simple moving average is $45.41 and its 200 day simple moving average is $51.70. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of 155.56 and a beta of 1.51.
In other Tabula Rasa HealthCare news, CAO Andrea Carolan Speers sold 3,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $48.23, for a total transaction of $168,805.00. Following the sale, the chief accounting officer now directly owns 48,607 shares in the company, valued at approximately $2,344,315.61. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Calvin H. Knowlton sold 22,223 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $46.79, for a total transaction of $1,039,814.17. Following the sale, the chief executive officer now owns 774,079 shares in the company, valued at $36,219,156.41. The disclosure for this sale can be found here. Insiders sold 103,313 shares of company stock valued at $4,759,106 in the last 90 days. Company insiders own 11.80% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in Tabula Rasa HealthCare by 4.0% during the 2nd quarter. BlackRock Inc. now owns 2,752,675 shares of the company’s stock worth $137,441,000 after buying an additional 105,190 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Tabula Rasa HealthCare by 18.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,315,216 shares of the company’s stock worth $65,669,000 after buying an additional 202,683 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in Tabula Rasa HealthCare by 26.3% during the 2nd quarter. Macquarie Group Ltd. now owns 728,027 shares of the company’s stock worth $36,350,000 after buying an additional 151,779 shares in the last quarter. Bank of America Corp DE lifted its holdings in Tabula Rasa HealthCare by 14.3% during the 2nd quarter. Bank of America Corp DE now owns 620,683 shares of the company’s stock worth $30,991,000 after buying an additional 77,578 shares in the last quarter. Finally, State Street Corp lifted its holdings in Tabula Rasa HealthCare by 2.7% during the 3rd quarter. State Street Corp now owns 546,513 shares of the company’s stock worth $30,025,000 after buying an additional 14,504 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Read More: How to build a Fibonacci channel
Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.